Back to the Top
The following message was posted to: PharmPK
Please could anyone help on this topic? I am aware that there was some
discussion back in February but would really appreciate some more
information on this.
It has been suggested that the assay limits and precision of
ligand-binding assays should be as stringent as those for small
molecules ie 15-20% CV. It has also been stated that this matter has
been discussed by the FDA and EMEA and agreement reached that there
should be no relaxation of the criteria for large molecules to 30%CV.
Please could someone provide me with a reference to any meetings the FDA
and EMEA may have held on this subject?
On a similar topic, could anyone tell me if there is a general consensus
on the use of "significant figures" for reporting analytical data and PK
parameters?
Thanks
Alan
HUNTINGDON LIFE.SCIENCES LIMITED
http://www.huntingdon.com
PharmPK Discussion List Archive Index page
Copyright 1995-2010 David W. A. Bourne (david@boomer.org)